US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CAR-T Concept

1,965.29

+47.812.49%

Number of Gainers:2

Number of Losers:- -

Number of Flat:- -

PE:- -

High:1,983.63

Open:1,945.09

Low:1,941.34

Close:1,917.48

Volume:14.49M

Turnover:2.22B

Market Cap:506.53B

Float Cap:490.64B

Loading ...

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Tariffs Influenced Novartis to Build Over 7 Plants in US, Trump Says

MT Newswires Live

Trump says ‘tariffs have influenced’ Novartis to build 7+ facilities

Gilead Sciences Inc Stock Moved Up by 3.72% on Feb 27: What Investors Need To Know

Atrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates

MT Newswires Live

Novartis completes acquisition of Avidity Biosciences

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

Novartis Says EMA Panel Recommends Remibrutinib for Chronic Spontaneous Urticaria

MT Newswires Live

Novartis receives positive CHMP opinion for remibrutinib in CSU

Arcellx FY 2025 collaboration revenue falls 79% to USD 22.3 million

Gilead Says HIV Treatment Trial Results Show Efficacy

Gilead presents new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data

Merck's New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care. -- Barrons.com

Novartis to build radioligand therapy site in Denton, Texas

Gilead: Strategic Arcellx Acquisition and Anito-cel Pipeline Strength Underpin Buy Rating and $162 Target

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared To Competitors

Gilead FY 2025 net income attributable to shareholders hits USD 8.5 billion (NM)

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Janux Therapeutics Inc (JANX) and CVS Health (CVS)

RPT-BREAKINGVIEWS-An $8 bln pharma deal prices patent fears

Gilead Sciences (GILD) Receives a Buy from Scotiabank

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4578/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1965.2883,"timestamp":1772225999999,"preClose":1917.4781,"halted":0,"volume":14486390,"delay":0,"changeRate":0.024934,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":47.810181,"latestTime":"02-27 16:00:00 EST","open":1945.0911,"high":1983.6273,"low":1941.3447,"amount":2219591512.699692,"amplitude":0.022051,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.241403,"peRate":22.158808,"turnoverRate":0.004743,"increases":2,"decrements":0,"flats":0,"marketCap":506526171136,"floatMarketCap":490638278656},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1983.6273,"amplitude":0.022051,"preClose":1917.4781,"low":1941.3447,"pbRate":"7.241403","latestPrice":1965.2883,"volume":14486390,"delay":0,"open":1945.0911,"prevYearClose":1612.5378,"prevWeekClose":1933.849,"prevMonthClose":1784.5848,"prevQuarterClose":1612.5378,"fiveDayClose":1933.849,"twentyDayClose":1775.8107,"sixtyDayClose":1554.292,"secType":"PLATE","market":"US","turnoverRate":0.004743,"peRate":22.158808,"marketCap":506526171136,"floatMarketCap":490638278656,"timestamp":1772225999999,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":2,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614867946","title":"Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2614867946","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614867946?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:35","pubTimestamp":1772228100,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  rose 3.60% to $148.95 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index  falling 0.43% to 6,878.88 and Dow Jones Industrial Average  falling 1.05% to 48,977.92.The stock's rise snapped a four-day losing streak.Gilead Sciences Inc. closed 5.30% short of its 52-week high of $157.29, which the company achieved on February 11th.The stock outperformed some of its competitors Friday, as Johnson & Johnson  rose 2.04% to $248.43, Pfizer Inc.  rose 2.03% to $27.65, and Abbott Laboratories  rose 0.08% to $116.35.Trading volume  eclipsed its 50-day average volume of 7.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled February 27, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Jour","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF631.EUR","LU1037948541.HKD","LU1066051498.USD","IE00B3T34201.USD","IE00BVYPNV92.GBP","LU1732800096.USD","LU2211815571.USD","LU0070217475.USD","LU0345769631.USD","LU0225771236.USD","LU2112291526.USD","SG9999002232.USD","LU2089984988.USD","LU0320765646.SGD","IE00BN8TJ469.HKD","LU1244550221.USD","LU1162221912.USD","LU0795875169.SGD","LU2471134796.USD","LU0965508806.USD","LU0985481810.HKD","BK4592","LU1894683348.USD","SG9999011175.SGD","LU2430703251.USD","LU0689626769.HKD","LU2129689605.HKD","LU0882574055.USD","LU0795875086.SGD","BK4504","BK4550","IE00BSNM7G36.USD","IE00BFTCPJ56.SGD","LU1989763690.USD","LU2129689431.USD","SG9999001176.USD","LU1261432733.SGD","LU1571399168.USD","BK4568","SG9999001440.SGD","LU2468319806.SGD","LU0345770308.USD","LU0683600562.USD","LU0114720955.EUR","LU1032466523.USD","LU1066051225.USD","IE00BFXG1179.USD","SG9999001176.SGD","LU0321505439.SGD","IE00B7SZLL34.SGD","LU0306806265.USD","LU1057294990.SGD","LU0456855351.SGD","LU0234572021.USD","LU2750360641.GBP","BK4559","SG9999015986.USD","LU0098860793.USD","LU1506573853.SGD","BK4599","LU2347655156.SGD","IE00B3PB1722.GBP","IE00BZ1G4Q59.USD","LU2133065610.SGD","IE0009355771.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","LU2602419157.SGD","SG9999015952.SGD","LU1691799644.USD","SG9999015945.SGD","LU1280957306.USD","LU1883839398.USD","LU1074936037.SGD","LU0124676726.USD","LU0170899867.USD","LU0289739699.SGD","IE00B2B36J28.USD","LU0787776722.HKD","IE00BVYPNW00.USD","LU1914381329.SGD","LU0234570918.USD","BK4007","LU0225284248.USD","BK4534","LU1196500208.SGD","IE00BLSP4452.SGD","LU1929549753.HKD","LU0889565916.HKD","LU1244550494.USD","BK4581","LU0640476718.USD","LU2471134879.HKD","LU1066051811.HKD","IE00B1BXHZ80.USD","LU0868494617.USD","BK4585","LU0432979614.USD","LU0823416689.USD","LU0861579265.USD","LU0203347892.USD","IE00BDGV0183.EUR","LU1066053197.SGD","LU0912757837.SGD","LU0466842654.USD","SGXZ57979304.SGD","LU2505996509.AUD","LU2324357040.USD","LU1061106388.HKD","LU1894683264.USD","LU2750360997.AUD","IE00B19Z3581.USD","IE00B42XCP33.USD","LU2237957811.SGD","SG9999002224.SGD","LU1674673691.USD","LU1839511570.USD","BK4532","LU1778281490.HKD","LU0792757196.USD","LU1059921491.USD","LU2129689514.USD","SGXZ41872573.SGD","IE00BLSP4239.USD","BK4533","BK4588","IE0001KFT4U8.USD","GILD","LU1718418525.SGD","LU1244550577.SGD","IE00B4R5TH58.HKD","IE0034235303.USD","LU0889566641.SGD","LU0965509101.SGD","LU1585245621.USD","SG9999003800.SGD","SG9999015978.USD","LU0122379950.USD","IE0002270589.USD","LU0985320562.USD","LU0965509010.AUD","LU2592432038.USD","LU1430594728.SGD","SG9999013999.USD","LU1983299246.USD","LU0965509283.SGD","LU1989763427.SGD","SGXZ23171101.USD","LU1221951129.SGD","LU0203345920.USD","LU0321505868.SGD","LU1674673428.USD","LU1032955483.USD","LU1721429402.USD","LU1496350502.SGD","BK4578","LU0320765992.SGD","IE000M9KFDE8.USD","LU0058720904.USD","BK4139","LU1221951046.USD","IE00BJJMRZ35.SGD","LU1267930813.SGD","LU2471134952.CNY","SG9999004303.SGD","LU1037948897.HKD","LU2505996681.GBP","IE00BBT3K403.USD","LU0345770993.USD","LU2237957902.USD","LU2471134523.USD","LU2087621335.USD","BK4566","LU1935042991.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","LU2430703178.SGD","BK4583","LU0266013472.USD","LU0306807586.USD","LU1732799900.SGD","LU1721429741.USD","LU2430703095.HKD","IE00BKVL7J92.USD","BK4082","LU0109394709.USD","LU0345769128.USD"],"gpt_icon":0},{"id":"2614869499","title":"Tariffs Influenced Novartis to Build Over 7 Plants in US, Trump Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2614869499","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614869499?lang=en_us&edition=fundamental","pubTime":"2026-02-28 02:43","pubTimestamp":1772217786,"startTime":"0","endTime":"0","summary":"Price: 169.41, Change: +3.90, Percent Change: +2.36","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BGSX","IE00BJJMRZ35.SGD","LU0208291251.USD","IE00B4R5TH58.HKD","LU0211331839.USD","LU0320765489.SGD","IE00BJT1NW94.SGD","NVS","BK4588","BK4007","IE00B2B36J28.USD","BK4585","IE00BFTCPJ56.SGD","IE0009355771.USD","BK4532","BK4578","IE0002141913.USD","LU0070302665.USD"],"gpt_icon":0},{"id":"2614186916","title":"Trump says ‘tariffs have influenced’ Novartis to build 7+ facilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2614186916","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614186916?lang=en_us&edition=fundamental","pubTime":"2026-02-28 02:35","pubTimestamp":1772217341,"startTime":"0","endTime":"0","summary":"President Donald Trump stated in a post to Truth Social: “Tariffs have influenced Novartis (NVS), and its great leader, Vasant (Vas) Narasimhan, M....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/trump-says-tariffs-have-influenced-novartis-to-build-7-facilities-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/trump-says-tariffs-have-influenced-novartis-to-build-7-facilities-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0211331839.USD","BK4007","BK4585","IE00BJT1NW94.SGD","LU0070302665.USD","LU0208291251.USD","LU0320765489.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","NVS","IE0009355771.USD","BK4578","BK4532","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4588"],"gpt_icon":0},{"id":"2614869659","title":"Gilead Sciences Inc Stock Moved Up by 3.72% on Feb 27: What Investors Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2614869659","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614869659?lang=en_us&edition=fundamental","pubTime":"2026-02-28 02:15","pubTimestamp":1772216124,"startTime":"0","endTime":"0","summary":"• Gilead Sciences is acquiring Arcellx, Inc. for $7.8 billion.\n• Gilead reported a 5% increase in Q4 product sales to $7.9 billion.\n• FDA approved expanded use for Gilead's Yescarta lymphoma treatment.","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/stocks/261630467-market-movers-gild-20260227","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0861579265.USD","ENSC","BK4532","IE00BKVL7J92.USD","LU1023059063.AUD","EDSA","LU1037948897.HKD","LU1066053197.SGD","LU0889565916.HKD","LU2087621335.USD","LU0823416689.USD","LU1066051498.USD","LU1037948541.HKD","IE00B3T34201.USD","LU0114720955.EUR","IE00B7SZLL34.SGD","LU0965509101.SGD","LU1839511570.USD","BK4007","LU0122379950.USD","LU1571399168.USD","BK4211","LU1057294990.SGD","IE00BZ1G4Q59.USD","LU2324357040.USD","LU0109394709.USD","SG9999015945.SGD","IE00B19Z3581.USD","IE0002270589.USD","LU1585245621.USD","LU1430594728.SGD","SG9999015978.USD","ISBC","BK4550","IE00B19Z3B42.SGD","LU1061106388.HKD","BK4583","LU0289739699.SGD","BK4588","LU2112291526.USD","IE00BSNM7G36.USD","BK4578","LU2468319806.SGD","BK4568","GILD","BK4566","IXHL","LU0058720904.USD","LU0234570918.USD","BK4585"],"gpt_icon":0},{"id":"2614850908","title":"Atrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2614850908","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614850908?lang=en_us&edition=fundamental","pubTime":"2026-02-27 23:32","pubTimestamp":1772206324,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics  said Friday it has started operations as an independent, publicly traded company with lead precision cardiology candidates ATR 1072 and ATR 1086.The company also said it has about $270 million in cash and cash equivalents, and two undisclosed research targets.Atrium said ATR 1072 is currently in preclinical studies for PRKAG2 syndrome, with an investigational new drug filing expected in H2, while ATR 1086 is expected to enter preclinical studies this year for phospholamban cardiomyopathy, with an IND filing targeted in 2027.Atrium was spun out of Avidity Biosciences as part of Avidity's acquisition by Novartis . The acquisition was completed Friday, Novartis said.Shares of Atrium Therapeutics were down 2.7% in recent Friday trading.Price: 13.79, Change: -0.99, Percent Change: -6.71","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B2B36J28.USD","IE0009354923.USD","LU0320765489.SGD","BK4578","IE0009355771.USD","BK4585","IE00B4R5TH58.HKD","LU0211331839.USD","LU0070302665.USD","IE0002141913.USD","LENZ","BK4505","BK4007","BK4532","IE00BJJMRZ35.SGD","BK4588","NVS","BK4139","BK4539","RNA","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0208291251.USD"],"gpt_icon":0},{"id":"2614546848","title":"Novartis completes acquisition of Avidity Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2614546848","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614546848?lang=en_us&edition=fundamental","pubTime":"2026-02-27 22:11","pubTimestamp":1772201464,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that it has successfully completed its acquisition of Avidity Biosciences (RNA). With the completion of the acquisition, A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-completes-acquisition-of-avidity-biosciences-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-completes-acquisition-of-avidity-biosciences-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0208291251.USD","IE0009355771.USD","RNA","BK4578","LU0320765489.SGD","BK4505","BK4588","IE00B2B36J28.USD","IE0009354923.USD","BK4007","IE00BJJMRZ35.SGD","LU0070302665.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0211331839.USD","NVS","BK4585","IE00BJT1NW94.SGD","BK4532","BK4139","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2614542748","title":"Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2614542748","media":"GlobeNewswire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614542748?lang=en_us&edition=fundamental","pubTime":"2026-02-27 22:00","pubTimestamp":1772200800,"startTime":"0","endTime":"0","summary":"Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-billi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/27/3246557/0/en/Novartis-successfully-completes-acquisition-of-Avidity-Biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xRNA-strategy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","IE00B4R5TH58.HKD","IE0009354923.USD","IE0009355771.USD","RNA","BK4585","LU0070302665.USD","IE0002141913.USD","BK4588","LU0320765489.SGD","IE00BFTCPJ56.SGD","BK4007","IE00BJJMRZ35.SGD","BK4139","IE00B2B36J28.USD","NVS","BK4505","BK4578","IE00BJT1NW94.SGD","LU0211331839.USD","LU0208291251.USD"],"gpt_icon":0},{"id":"2614512856","title":"Novartis Says EMA Panel Recommends Remibrutinib for Chronic Spontaneous Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2614512856","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614512856?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:56","pubTimestamp":1772197000,"startTime":"0","endTime":"0","summary":"Novartis  said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended marketing authorization for remibrutinib as an oral treatment for chronic spontaneous urticaria in adults with inadequate response to H1-antihistamines.The European Commission is expected to act on the CHMP's positive opinion and issue a decision in about two months, the company said.The CHMP recommendation was backed by results from two phase 3 trials in which remibrutinib showed improvements in itch and hives as early as the first week, with benefits sustained for 52 weeks, Novartis said.The drug also showed improvements in quality of life and sleep and a favorable safety profile, the company said.Chronic spontaneous urticaria refer to hives that last for six weeks or longer, and are caused by no external trigger or allergen.Shares of Novartis were up 1.8% in recent premarket activity Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJT1NW94.SGD","EMA","NVS","LU0211331839.USD","BK4007","BK4081","IE00B4R5TH58.HKD","IE00B2B36J28.USD","BK4532","BK4585","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","BK4578","IE0002141913.USD","LU0320765489.SGD","BK4588","IE0009355771.USD","LU0070302665.USD","LU0208291251.USD"],"gpt_icon":0},{"id":"2614858317","title":"Novartis receives positive CHMP opinion for remibrutinib in CSU","url":"https://stock-news.laohu8.com/highlight/detail?id=2614858317","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614858317?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:55","pubTimestamp":1772193315,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a positi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-receives-positive-chmp-opinion-for-remibrutinib-in-csu-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-receives-positive-chmp-opinion-for-remibrutinib-in-csu-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IE00B4R5TH58.HKD","LU0070302665.USD","IE0002141913.USD","BK4578","BK4532","IE00B2B36J28.USD","BK4585","BK4087","IE00BJT1NW94.SGD","LU0208291251.USD","IE0009355771.USD","LU0320765489.SGD","CHMP","LU0211331839.USD","BK4007","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","NVS"],"gpt_icon":0},{"id":"2614071148","title":"Arcellx FY 2025 collaboration revenue falls 79% to USD 22.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614071148","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614071148?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:44","pubTimestamp":1772142258,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcellx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDLc6VQr7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","LU0122379950.USD","ACLX","SG9999015978.USD","LU0965508806.USD","IE00B7SZLL34.SGD","LU1066053197.SGD","LU1066051498.USD","LU1839511570.USD","SG9999015986.USD","LU0965509010.AUD","LU0114720955.EUR","IE00BKVL7J92.USD","GILD","LU0965509283.SGD","BK4139","BK4532","LU1571399168.USD","LU0823416689.USD","IE0002270589.USD","IE00BSNM7G36.USD","LU0889565916.HKD","IE00B19Z3B42.SGD","LU1674673428.USD","LU2087621335.USD","BK4588","LU2089984988.USD","SG9999015952.SGD","BK4550","LU0234570918.USD","LU1061106388.HKD","BK4568","IE00B3T34201.USD","LU0861579265.USD","LU1037948541.HKD","LU1778281490.HKD","LU1037948897.HKD","LU1057294990.SGD","LU2324357040.USD","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","SG9999015945.SGD","LU2112291526.USD","LU2468319806.SGD","LU0320765992.SGD","LU1430594728.SGD","LU1585245621.USD","BK4583","BK4585","LU0882574055.USD"],"gpt_icon":0},{"id":"2614058592","title":"Gilead Says HIV Treatment Trial Results Show Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2614058592","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614058592?lang=en_us&edition=fundamental","pubTime":"2026-02-26 03:08","pubTimestamp":1772046480,"startTime":"0","endTime":"0","summary":"Gilead Sciences posted results from a Phase 3 trial showing its HIV treatment was effective.The trial of bictegravir 75 mg/lenacapavir 50 mg was also well-tolerated and demonstrated the potential to broaden into options for adults with virological suppression, the company said.The Foster City, Calif., company said the treatment offered comparable efficacy to Biktarvy and treatment with complex multi-tablet regimens.\"We look forward to working with regulatory authorities to potentially bring this combination forward to people with HIV,\" said Jared Baeten, Gildead's virology therapeutic head.Bictegravir and lenacapavir in combination are investigational and not approved anywhere globally.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673691.USD","LU2087621335.USD","LU2112291526.USD","LU1066053197.SGD","LU1037948897.HKD","LU1571399168.USD","LU1057294990.SGD","LU1778281490.HKD","LU0234570918.USD","LU0114720955.EUR","LU1674673428.USD","LU0889565916.HKD","LU1023059063.AUD","SG9999015986.USD","IE00BSNM7G36.USD","BK4588","LU0320765992.SGD","SG9999015978.USD","LU0965509010.AUD","LU1585245621.USD","BK4139","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU0861579265.USD","LU0823416689.USD","LU1037948541.HKD","LU1061106388.HKD","IE00B19Z3581.USD","BK4566","LU1839511570.USD","BK4568","GILD","LU0058720904.USD","SG9999015945.SGD","LU0965509283.SGD","LU1430594728.SGD","LU1066051498.USD","LU0882574055.USD","BK4585","SG9999015952.SGD","BK4583","BK4550","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU0122379950.USD","LU2089984988.USD","LU2324357040.USD","BK4578","BK4532","IE0002270589.USD"],"gpt_icon":0},{"id":"2614305833","title":"Gilead presents new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2614305833","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614305833?lang=en_us&edition=fundamental","pubTime":"2026-02-26 02:51","pubTimestamp":1772045480,"startTime":"0","endTime":"0","summary":"Gilead (GILD) Sciences announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-presents-new-phase-3-artistry-1-and-artistry-2-trial-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-presents-new-phase-3-artistry-1-and-artistry-2-trial-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1839511570.USD","BK4566","LU0965509101.SGD","IE00BZ1G4Q59.USD","SG9999015945.SGD","LU1037948897.HKD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU0058720904.USD","LU2468319806.SGD","BK4585","LU1430594728.SGD","LU0320765992.SGD","IE00B19Z3B42.SGD","LU0823416689.USD","LU1037948541.HKD","LU1061106388.HKD","LU1057294990.SGD","BK4139","SG9999015952.SGD","BK4583","SG9999015986.USD","LU0114720955.EUR","LU0122379950.USD","LU2324357040.USD","BK4578","LU0861579265.USD","LU0289739699.SGD","LU2089984988.USD","SG9999015978.USD","LU0965508806.USD","LU1674673428.USD","BK4532","IE00BSNM7G36.USD","GILD","LU0889565916.HKD","LU0965509283.SGD","IE00BKVL7J92.USD","LU0965509010.AUD","LU1585245621.USD","IE00B3T34201.USD","LU2112291526.USD","LU0234570918.USD","LU1023059063.AUD","LU0882574055.USD","BK4550","LU1066051498.USD","LU1571399168.USD","BK4588","IE0002270589.USD"],"gpt_icon":0},{"id":"2614032765","title":"Merck's New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2614032765","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614032765?lang=en_us&edition=fundamental","pubTime":"2026-02-26 01:38","pubTimestamp":1772041080,"startTime":"0","endTime":"0","summary":"With years to go before Merck loses patent protection for its biggest revenue driver, all eyes are on the company to find a new miracle drug. It seems Merck may be on the right path.On Wednesday, the drugmaker presented results from Phase 3 trials evaluating the efficacy of its once-daily, oral regimen of doravirine and islatravir in adults with HIV-1. The trial evaluated the regimen's success in preventing HIV-1 replication using viral load, a measure of the amount of HIV genetic material in the blood.The two-drug regimen was compared with Biktarvy, a three-drug regimen from Gilead Sciences, in a patient population that hadn't previously received antiretroviral treatment.\"Competition is not a dirty word,\" Barr said. \"It is a terrific stimulant of a sense of urgency.\" Merck's \"credo\" is that \"if it's good for the patient, it's good for the company and ultimately it's good for the shareholder,\" he added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509010.AUD","LU0882574055.USD","LU2023250504.SGD","LU2087621335.USD","LU1974910355.USD","LU1057294990.SGD","LU1917777945.USD","BK4007","LU0234570918.USD","LU0265550359.USD","BK4550","BK4533","BK4559","SG9999013999.USD","LU0122379950.USD","BK4139","LU0234572021.USD","BK4578","LU1162221912.USD","IE000M9KFDE8.USD","LU1989772840.SGD","LU0965509101.SGD","BK4532","IE00B19Z3581.USD","LU2125154935.USD","LU0130517989.USD","LU2360032135.SGD","SG9999015952.SGD","BK4585","LU1699723380.USD","LU1037948541.HKD","LU1093756325.SGD","LU1066051498.USD","IE00B1BXHZ80.USD","LU0861579265.USD","LU1061106388.HKD","SG9999015986.USD","LU0114720955.EUR","LU0070302665.USD","LU0889565916.HKD","LU0985320562.USD","IE00BBT3K403.USD","LU1023059063.AUD","IE00BSNM7G36.USD","LU0320765646.SGD","LU1839511570.USD","LU1571399168.USD","LU0208291251.USD","LU0320765992.SGD","SG9999001176.USD","BK4588","BK4516","LU2468319806.SGD","LU1291159041.SGD","IE0002141913.USD","LU2106854487.HKD","LU1066051225.USD","LU1066051811.HKD","SG9999015978.USD","LU0203345920.USD","IE00BKVL7J92.USD","SG9999015945.SGD","GILD","LU0098860793.USD","SG9999015341.SGD","LU0006306889.USD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","LU0266013472.USD","SG9999002224.SGD","LU1929549753.HKD","LU2089984988.USD","LU2361045086.USD","SG9999014575.USD","IE00BLSP4452.SGD","LU2023250843.SGD","SG9999015358.SGD","LU2461242641.AUD","LU1934455277.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","IE00BN8TJ469.HKD","LU0965509283.SGD","LU1983299246.USD","LU1116320901.HKD","LU0130102774.USD","SG9999014559.SGD","LU2361044865.SGD","IE00B3T34201.USD","LU1066053197.SGD","LU0648001328.SGD","LU2361044949.HKD","LU1674673691.USD","LU0058720904.USD","LU1201861249.SGD","LU1430594728.SGD","LU1585245621.USD","LU0265550946.USD","IE00B2B36J28.USD","SG9999014542.SGD","LU1116320737.USD","LU2112291526.USD","LU2125154778.USD","LU1989771016.USD","LU1037948897.HKD","LU1941712348.USD","LU1069347547.HKD","BK4583","IE0002270589.USD","LU0238689110.USD","LU0211331839.USD","LU1778281490.HKD","BK4568","IE00BLSP4239.USD","IE00BJJMRZ35.SGD","BK4566","LU0477156953.USD","LU0106261372.USD","LU1934455194.USD","LU2324357040.USD","LU0823416689.USD","IE00BZ1G4Q59.USD","LU0980610538.SGD","IE00B4R5TH58.HKD","LU1093756168.USD","LU1941712264.USD","IE00B7SZLL34.SGD","LU0109394709.USD","LU1989772923.USD","IE00BJT1NW94.SGD","IE0009355771.USD","SG9999001176.SGD","LU0320765489.SGD","BK4534","LU1035773651.USD","LU0965508806.USD","LU1674673428.USD","SG9999001440.SGD","SG9999002232.USD","LU0203347892.USD","LU1934455863.HKD","LU0432979614.USD","SG9999014567.USD","MRK"],"gpt_icon":0},{"id":"2614085081","title":"Novartis to build radioligand therapy site in Denton, Texas","url":"https://stock-news.laohu8.com/highlight/detail?id=2614085081","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614085081?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:16","pubTimestamp":1772021788,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced plans to establish a new 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas. This purpose-built RL...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-to-build-radioligand-therapy-site-in-denton-texas-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-to-build-radioligand-therapy-site-in-denton-texas-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4588","LU0320765489.SGD","LU0208291251.USD","BK4532","IE0002141913.USD","BK4578","NVS","LU0211331839.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0070302665.USD","IE0009355771.USD","BK4007","BK4585"],"gpt_icon":0},{"id":"2614888220","title":"Gilead: Strategic Arcellx Acquisition and Anito-cel Pipeline Strength Underpin Buy Rating and $162 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2614888220","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614888220?lang=en_us&edition=fundamental","pubTime":"2026-02-25 18:06","pubTimestamp":1772013999,"startTime":"0","endTime":"0","summary":"Analyst Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Gilead Sciences and keeping the price target at $162.00. Tazeen Ahm...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/gilead-strategic-arcellx-acquisition-and-anito-cel-pipeline-strength-underpin-buy-rating-and-162-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/gilead-strategic-arcellx-acquisition-and-anito-cel-pipeline-strength-underpin-buy-rating-and-162-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4550","SG9999015978.USD","IE0001KFT4U8.USD","LU0314106906.USD","LU0648001328.SGD","LU1880398471.USD","LU0868494617.USD","BAC","LU0098860793.USD","LU2087621335.USD","LU0965509283.SGD","BK4578","LU0640476718.USD","LU1366192091.USD","LU0234570918.USD","LU2324357040.USD","BK4583","LU1791807156.HKD","LU0477156797.USD","LU1894683348.USD","LU1430594728.SGD","LU0889565916.HKD","GILD","LU1496350171.SGD","LU0170899867.USD","LU0114720955.EUR","LU1037948897.HKD","LU1674673428.USD","SG9999015952.SGD","LU1267930227.SGD","LU0070302665.USD","LU1585245621.USD","LU2089984988.USD","LU1883839398.USD","SG9999015945.SGD","LU0149725797.USD","LU0256863811.USD","LU0208291251.USD","BK4568","BK4534","LU0203345920.USD","SG9999015986.USD","LU1496350502.SGD","LU2129689605.HKD","BK4532","LU0130102774.USD","LU0882574055.USD","LU0477156953.USD","LU0106831901.USD","LU0306806265.USD"],"gpt_icon":0},{"id":"2614408723","title":"Gilead Sciences Inc. Stock Underperforms Tuesday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2614408723","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614408723?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:35","pubTimestamp":1771968900,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  slipped 1.46% to $147.64 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 0.77% to 6,890.07 and the Dow Jones Industrial Average  rising 0.76% to 49,174.50.This was the stock's second consecutive day of losses.Gilead Sciences Inc. closed 6.14% below its 52-week high of $157.29, which the company reached on February 11th.The stock underperformed when compared to some of its competitors Tuesday, as Johnson & Johnson  rose 0.71% to $246.28, Pfizer Inc.  rose 0.30% to $27.14, and Abbott Laboratories  fell 0.62% to $114.58.Trading volume  eclipsed its 50-day average volume of 7.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled February 24, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones News","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985320562.USD","BK4566","LU0225284248.USD","LU2505996681.GBP","IE00BJJMRZ35.SGD","LU2471134796.USD","BK4599","LU0345769631.USD","LU1894683264.USD","BK4082","LU1244550221.USD","LU1894683348.USD","LU0114720955.EUR","BK4578","LU2089984988.USD","LU0965508806.USD","IE00B42XCP33.USD","IE00BSNM7G36.USD","GILD","IE00B1BXHZ80.USD","IE0001KFT4U8.USD","LU1221951046.USD","LU1914381329.SGD","LU0456855351.SGD","LU0306807586.USD","LU2750360641.GBP","LU0170899867.USD","LU2112291526.USD","LU1989763690.USD","LU1023059063.AUD","LU1732800096.USD","BK4504","LU1221951129.SGD","BK4550","BK4581","IE00BVYPNW00.USD","LU0234572021.USD","LU0466842654.USD","LU0795875169.SGD","LU1496350502.SGD","LU0306806265.USD","LU0912757837.SGD","IE0009355771.USD","LU0965509101.SGD","SG9999015945.SGD","LU0070217475.USD","LU1721429741.USD","IE00B19Z3581.USD","LU2592432038.USD","LU2430703251.USD","LU2468319806.SGD","LU1066051225.USD","LU1674673691.USD","IE00BGHQF631.EUR","LU1061106388.HKD","BK4534","BK4139","IE00BVYPNV92.GBP","BK4583","LU2471134952.CNY","SG9999015952.SGD","IE00B4R5TH58.HKD","LU1506573853.SGD","BK4568","LU2505996509.AUD","BK4007","SG9999003800.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE00BKVL7J92.USD","IE0002141913.USD","IE00B2B36J28.USD","IE00B3PB1722.GBP","LU2237957811.SGD","LU2750360997.AUD","SG9999004303.SGD","IE00BLSP4239.USD","LU0882574055.USD","LU0098860793.USD","LU1691799644.USD","LU0640476718.USD","LU0683600562.USD","LU1066051498.USD","SG9999002232.USD","LU1261432733.SGD","LU1778281490.HKD","BK4533","LU1066053197.SGD","LU1929549753.HKD","IE00BZ1G4Q59.USD","LU1989763427.SGD","BK4592","LU1883839398.USD","LU2471134879.HKD","IE00B7SZLL34.SGD","LU1162221912.USD","BK4559","IE00BN8TJ469.HKD","LU2430703178.SGD","LU0787776722.HKD","LU1196500208.SGD","LU0320765992.SGD","LU0823416689.USD","IE00BLSP4452.SGD","LU0689626769.HKD","LU1718418525.SGD","SG9999015986.USD","LU0792757196.USD","LU0122379950.USD","LU2324357040.USD","LU0861579265.USD","LU0266013472.USD","SG9999001176.USD","SG9999015978.USD","LU0889566641.SGD","BK4532","LU1244550577.SGD","LU0889565916.HKD","LU0985481810.HKD","LU0321505439.SGD","LU0124676726.USD","LU0795875086.SGD","LU1585245621.USD","SG9999013999.USD","LU0203345920.USD","IE0034235303.USD","LU2347655156.SGD","LU0234570918.USD","LU0321505868.SGD","LU1032466523.USD","LU1066051811.HKD","LU0965509283.SGD","LU0345770993.USD","IE00BDGV0183.EUR","IE00BFXG1179.USD","IE000M9KFDE8.USD","LU1839511570.USD","LU2602419157.SGD","SGXZ57979304.SGD","LU1059921491.USD","SGXZ23171101.USD","LU1037948897.HKD","LU1935042991.SGD","LU1074936037.SGD","LU2471134523.USD","LU0320765646.SGD","LU1732799900.SGD","LU0058720904.USD","LU1280957306.USD","LU0432979614.USD","BK4588","BK4585","LU1267930813.SGD","LU1430594728.SGD","LU1721429402.USD","IE00B19Z3B42.SGD","LU1037948541.HKD","LU2129689431.USD","LU2211815571.USD","LU1057294990.SGD","SGXZ41872573.SGD","LU0868494617.USD","LU2129689605.HKD","LU0289739699.SGD","SG9999001176.SGD","LU1674673428.USD","LU1032955483.USD","LU0345769128.USD","LU2133065610.SGD","LU0965509010.AUD","LU1983299246.USD","LU1244550494.USD","LU0109394709.USD","IE00B3T34201.USD","LU0203347892.USD","LU2129689514.USD","SG9999001440.SGD","LU2087621335.USD","LU0345770308.USD","SG9999011175.SGD","LU2430703095.HKD","IE00BBT3K403.USD","LU1571399168.USD","SG9999002224.SGD","LU0225771236.USD","LU2237957902.USD","IE0002270589.USD"],"gpt_icon":0},{"id":"2614372368","title":"Gilead FY 2025 net income attributable to shareholders hits USD 8.5 billion (NM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614372368","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614372368?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:26","pubTimestamp":1771968369,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 24, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDLbdM5n1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","LU0861579265.USD","BK4139","LU0234570918.USD","LU1674673691.USD","LU0058720904.USD","LU0320765992.SGD","IE00BSNM7G36.USD","LU1023059063.AUD","LU0965508806.USD","BK4583","LU1037948541.HKD","SG9999015945.SGD","BK4550","LU1037948897.HKD","BK4578","LU1061106388.HKD","LU1778281490.HKD","LU0889565916.HKD","LU1585245621.USD","LU1057294990.SGD","LU0289739699.SGD","LU2087621335.USD","SG9999015952.SGD","LU0122379950.USD","IE00B19Z3581.USD","LU1674673428.USD","LU0882574055.USD","BK4588","SG9999015978.USD","IE00B3T34201.USD","LU0109394709.USD","LU1066051498.USD","LU0965509101.SGD","IE0002270589.USD","LU2324357040.USD","SG9999015986.USD","GILD","LU1430594728.SGD","LU2089984988.USD","BK4585","IE00BZ1G4Q59.USD","LU1571399168.USD","IE00B7SZLL34.SGD","IE00BKVL7J92.USD","LU2112291526.USD","LU0965509283.SGD","ACLX","BK4566","LU1066053197.SGD"],"gpt_icon":0},{"id":"2613717809","title":"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Janux Therapeutics Inc (JANX) and CVS Health (CVS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613717809","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613717809?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:50","pubTimestamp":1771941010,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD – Research Report), Janux Ther...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-janux-therapeutics-inc-janx-and-cvs-health-cvs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-janux-therapeutics-inc-janx-and-cvs-health-cvs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1061106388.HKD","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","LU0889565916.HKD","BK4550","SG9999015986.USD","LU1983299246.USD","LU0965509101.SGD","LU2324357040.USD","LU0208291251.USD","IE00BZ1G4Q59.USD","LU0061475181.USD","IE00B3T34201.USD","BK4539","LU0070302665.USD","LU0114720955.EUR","LU0122379950.USD","LU0432979614.USD","LU0823416689.USD","LU0234570918.USD","LU1023059063.AUD","JANX","LU0965508806.USD","LU0965509010.AUD","LU1571399168.USD","LU1430594728.SGD","LU0162691827.USD","BK4585","BK4137","GILD","LABU","IE00BKVL7J92.USD","LU1839511570.USD","BK4196","LU0109394709.USD","XLV","LU0128526141.USD","IE00BSNM7G36.USD","LU1674673428.USD","LU1699723380.USD","XBI","HCSG","LU2468319806.SGD","LU0320765992.SGD","CVS","BK4532","BK4578","BK4504","LU1585245621.USD","LU0211331839.USD"],"gpt_icon":0},{"id":"2613952711","title":"RPT-BREAKINGVIEWS-An $8 bln pharma deal prices patent fears","url":"https://stock-news.laohu8.com/highlight/detail?id=2613952711","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613952711?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:00","pubTimestamp":1771938000,"startTime":"0","endTime":"0","summary":"RPT-BREAKINGVIEWS-An $8 bln pharma deal prices patent fearsThe author is a Reuters Breakingviews columnist. The opinions expressed are his own.By Robert Cyran","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL6N3ZJ0VU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0098860793.USD","ACLX","IE00BJJMRZ35.SGD","SG9999011175.SGD","BK4534","LU0477156953.USD","LU0052756011.USD","LU1548497426.USD","LU2023251221.USD","LU1057294990.SGD","LU0528227936.USD","BK4568","LU2347655156.SGD","LU0114720955.EUR","LU2111349929.HKD","LU0314106906.USD","LU2361044949.HKD","LU0965509101.SGD","LU0053666078.USD","LU1989771016.USD","BK4550","IE00B1BXHZ80.USD","IE00B2B36J28.USD","LU1732799900.SGD","IE00BFTCPJ56.SGD","LU1244550494.USD","LU0965509283.SGD","IE000M9KFDE8.USD","LU0965508806.USD","LU2324357040.USD","LU0868494617.USD","LU1074936037.SGD","LU2129689605.HKD","IE00BBT3K403.USD","LU0256863902.USD","LU0267386448.USD","LU2087621335.USD","LU1880398554.USD","LU0417517546.SGD","LU1699723380.USD","LU0170899867.USD","LU0256863811.USD","LU0648000940.SGD","BK4585","SG9999015952.SGD","LU0208291251.USD","LU0683600562.USD","LU1201861165.SGD","LU0882574139.USD","LU1880398471.USD","SG9999002232.USD","IE0034235188.USD","SG9999014567.USD","LU0225771236.USD","IE00BFXG1179.USD","LU0225284248.USD","LU1496350502.SGD","LU1674673691.USD","LU1934455863.HKD","LU0965509010.AUD","IE00B19Z3581.USD","LU1989772840.SGD","SGXZ57979304.SGD","LU1732800096.USD","IE00BZ1G4Q59.USD","BK4127","LU0314104364.USD","LU1934455194.USD","LU2360032135.SGD","BK4566","IE00BKVL7J92.USD","LU0234572021.USD","LU1430594728.SGD","LU2129689514.USD","LU0130518102.USD","LU0823416689.USD","LU1061106388.HKD","LU1983299246.USD","LU0158827948.USD","LU1035773651.USD","LU1720051108.HKD","IE0002141913.USD","LU1066051225.USD","LU0985481810.HKD","SG9999013999.USD","LU1037948897.HKD","LU1066053197.SGD","LU1929549753.HKD","LU1804176565.USD","LU2112291526.USD","BK4578","IE00BSNM7G36.USD","LU0795875169.SGD","LU0980610538.SGD","LU1791710582.SGD","LU2125154778.USD","LU0225283273.USD","LU1366192091.USD","BK4592","LU2361044865.SGD","LU0321505868.SGD","LU1037948541.HKD","LU1069347547.HKD","LU1506573853.SGD","LU1894683348.USD","LU0265550359.USD","LU1585245621.USD","LU2129689431.USD","IE00B4R5TH58.HKD","LU1974910355.USD","LU0648001328.SGD","SG9999014575.USD","LU0432979614.USD","LU1116320737.USD","SG9999014559.SGD","LU0266013472.USD","IE00BLSP4239.USD","LU2133065610.SGD","LU0320765646.SGD","BK4588","LU1674673428.USD","LU1363072403.SGD","LU2089283258.USD","BK4504","LU0130517989.USD","LU0882574055.USD","LU1668664300.SGD","LU2265009873.SGD","LU1778281490.HKD","LU2271345857.HKD","BK4139","LU1280957306.USD","LU1571399168.USD","SG9999003800.SGD","SG9999001176.USD","IE00B7SZLL34.SGD","LU2023250504.SGD","LU0234570918.USD","GILD","SG9999015945.SGD","LU0211331839.USD","LU1093756325.SGD","LU2357305700.SGD","LU2361045086.USD","BK4007","IE0002270589.USD","LU0557290698.USD","LU0265550946.USD","LU1066051498.USD","LU1116320901.HKD","LU2028103732.USD","LU2089984988.USD","LU0310800965.SGD","LU0320765489.SGD","LU0456855351.SGD","LU0971096721.USD","IE00B3T34201.USD","LU1941712264.USD","SG9999002224.SGD","LU2468319806.SGD","SG9999014542.SGD","LU0861579265.USD","LU1066051811.HKD","IE0001KFT4U8.USD","BK4532","LU1941712348.USD","LU0109394709.USD","LU0203345920.USD","LU1023059063.AUD","LU2125154935.USD","SG9999001440.SGD","LU0122379950.USD","LU1244550221.USD","BK4533","LU0203347892.USD","LU0238689110.USD","LU0912757837.SGD","LU0889565916.HKD","SG9999015341.SGD","BK4581","LU0149725797.USD","LU0321505439.SGD","LU0289739699.SGD","LU0320765992.SGD","LU1839511570.USD","BK4599","LU1162221912.USD","LU0070302665.USD","LU1720051017.SGD","LU1244550577.SGD","LU0106261372.USD","LU1291159041.SGD","LU0306807586.USD","LU1267930227.SGD","LU0130103400.USD","SG9999015358.SGD","LU0006306889.USD","BK4207","IE00B19Z3B42.SGD","LU1894683264.USD","LU2023250843.SGD","SG9999001176.SGD","LU1718418525.SGD","LU1496350171.SGD","LU0795875086.SGD","LU1934455277.USD","IE0009355771.USD","LU1791710400.SGD","LU1093756168.USD","LU2106854487.HKD","SG9999015978.USD","BK4553","IE00BN8TJ469.HKD","LU2461242641.AUD","LU0787776722.HKD","LU1791807156.HKD","LU0477156797.USD","LU1883839398.USD","LU0640476718.USD","LU0130102774.USD","BK4583","BK4516","LU1917777945.USD","LU0158827781.USD","LU0058720904.USD","LU0985320562.USD","LU1989772923.USD","LU2089284900.SGD","SG9999015986.USD","IE00BLSP4452.SGD","LU0106831901.USD","LU0306806265.USD","LU1201861249.SGD","LU0128525689.USD","IE00BJT1NW94.SGD","BK4559"],"gpt_icon":0},{"id":"2613674713","title":"Gilead Sciences (GILD) Receives a Buy from Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2613674713","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613674713?lang=en_us&edition=fundamental","pubTime":"2026-02-24 19:36","pubTimestamp":1771933005,"startTime":"0","endTime":"0","summary":"Scotiabank analyst Louise Chen maintained a Buy rating on Gilead Sciences today and set a price target of $177.00. According to TipRanks, Chen is a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-receives-a-buy-from-scotiabank-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-receives-a-buy-from-scotiabank-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4550","LU1023059063.AUD","LU1778281490.HKD","SG9999015978.USD","LU0320765992.SGD","BK4566","LU1061106388.HKD","LU0965509101.SGD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","LU0109394709.USD","LU2087621335.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU0965509010.AUD","LU1674673691.USD","LU2112291526.USD","LU0058720904.USD","LU0965509283.SGD","BK4578","LU0234570918.USD","LU2324357040.USD","BK4583","LU0965508806.USD","LU1430594728.SGD","GILD","LU1037948897.HKD","LU0114720955.EUR","SG9999015952.SGD","LU1585245621.USD","LU0861579265.USD","LU2089984988.USD","LU1037948541.HKD","SG9999015945.SGD","LU1066051498.USD","BK4568","LU1571399168.USD","LU0289739699.SGD","LU1057294990.SGD","LU0122379950.USD","SG9999015986.USD","LU1066053197.SGD","BK4532","LU0882574055.USD","IE0002270589.USD","LU0823416689.USD","LU2468319806.SGD","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":53,"code":"91000000","status":"200"}]}}